A review of the evidence for occupational exposure risks to novel anticancer agents - A focus on monoclonal antibodies

Conclusion Novel agents are rapidly emerging into clinical practice, and healthcare personnel have few resources to evaluate risk and provide safety recommendations. Novel agents possess differing physical, molecular and pharmacological profiles compared to traditional cytotoxic anticancer agents. Evaluation of occupational exposure risk should consider both toxicity and internalisation. Evidence-based guidance able to direct safe handling practices for novel anticancer agents across a variety of clinical settings is urgently required.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Tags: Review Articles Source Type: research